9 recruiting, 6 completed, 3 active not recruiting, 2 terminated. 10 Phase 2, 8 Phase 1, 6 Not applicable, 1 Early Phase 1, 1 Phase 3.
Follow Metastatic Sarcoma: new trials by email Literature Review of Metastatic Sarcoma trials Research Report on Metastatic Sarcoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| 64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer 64Cu-LNTH-1363S - Metastatic Sarcoma, Esophageal Cancer | Phase 1 / Phase 2 | Recruiting | Lantheus Medical Imaging | 26 | 2025-08-01 | 2025-08-12 |
| A Checklist (Advanced Care Planning) for The Assessment of Mobility Needs in Patients With Sarcoma Assessment, Questionnaire Administration, Interview - Metastatic Sarcoma, Sarcoma | Not applicable | Completed | Fred Hutchinson Cancer Center | 27 | 2025-07-08 | 2026-05-12 |
| Targeted Oligometastatic Radiation in Pediatric and Young Adult Patients With Soft Tissue and Bone Sarcoma Consolidative radiation therapy (cRT) - Metastatic Sarcoma, Radiation Therapy Patient | Not applicable | Recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 70 | 2025-03-25 | 2026-07-13 |
| Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma Doxorubicin, Doxorubicin Hydrochloride, Drug Delivery Microdevice - Metastatic Sarcoma, Recurrent Sarcoma | Not applicable | Recruiting | M.D. Anderson Cancer Center | 20 | 2025-02-25 | 2026-08-11 |
| Safety and Feasibility of Intraoperative Visualization With Cytalux in Children Cytalux - Osteosarcoma, Pulmonary Metastasis | Phase 1 | Recruiting | Ann & Robert H Lurie Children's Hospital of Chicago | 10 | 2024-04-08 | 2026-06-05 |
| Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma Biopsy Procedure, Biospecimen Collection, Computed Tomography - Metastatic Dedifferentiated Liposarcoma, Metastatic Leiomyosarcoma | Phase 1 | Recruiting | National Cancer Institute (NCI) | 30 | 2024-02-06 | 2026-11-04 |
| Study of the Impact of Digital Health Interventions on Symptom & Side-Effect Management in Metastatic Sarcoma Patients Digital support - Advanced Sarcoma, Metastatic Sarcoma | Not applicable | Recruiting | CareAcross | 108 | 2023-08-22 | 2026-06-11 |
| YH001 Plus Envafolimab With or Without Doxorubicin in Patients With Advanced or Metastatic Sarcoma YH001, Envafolimab, Doxorubicin - Advanced Sarcoma, Metastatic Sarcoma | Phase 1 / Phase 2 | Unknown | Tracon Pharmaceuticals Inc. | 15 | 2022-11-14 | 2023-09-21 |
| A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas Gemcitabine, Docetaxel, 9-ING-41 - Sarcoma, Soft Tissue Sarcoma | Phase 2 | Withdrawn | Brown University | 2021-09-01 | 2021-07-28 | |
| Testing the Anti-cancer Drug, Rogaratinib (BAY 1163877), for Treatment of Advanced Sarcoma With Alteration in Fibroblast Growth Factor Receptor (FGFR 1-4), and in Patients With SDH-deficient Gastrointestinal Stromal Tumor (GIST) Biopsy Procedure, Biospecimen Collection, Computed Tomography - Locally Advanced Gastrointestinal Stromal Tumor, Locally Advanced Sarcoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 48 | 2021-05-03 | 2026-07-31 |
| Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial Cryosurgery, Quality-of-Life Assessment, Stereotactic Body Radiation Therapy - Castration-Resistant Prostate Carcinoma, Metastatic Colorectal Carcinoma | Not applicable | Recruiting | M.D. Anderson Cancer Center | 40 | 2021-03-16 | 2026-04-15 |
| Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors Avapritinib - Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 50 | 2021-01-20 | 2026-06-11 |
| 68Ga-FAPi-46 PET/CT Scan in Imaging Patients With Sarcoma Computed Tomography, Gallium Ga 68 FAPi-46, Positron Emission Tomography - Metastatic Sarcoma, Recurrent Sarcoma | Early Phase 1 | Active not recruiting | Jonsson Comprehensive Cancer Center | 18 | 2020-09-08 | 2026-09-17 |
| Microwave Ablation or Wedge Resection for the Treatment of Lung, Sarcoma and Colorectal Lesions, ALLUME Study Computed Tomography with Contrast, Microwave Ablation, Questionnaire Administration - Lung Non-Small Cell Carcinoma, Metastatic Colorectal Carcinoma | Active not recruiting | M.D. Anderson Cancer Center | 74 | 2019-08-07 | 2026-10-07 | |
| Intravital Microscopy in Human Solid Tumors Diagnostic Microscopy, Fluorescein Sodium Injection - Solid Tumor, Adult, Clinical Stage IV Gastric Cancer AJCC v8 | Not applicable | Recruiting | Mayo Clinic | 85 | 2019-02-28 | 2026-06-02 |
| A Phase 3, Randomized, Double-blind, Placebo-controlled Study For Subjects With Locally-advanced Unresectable or Metastatic Synovial Sarcoma (V943-003, IMDZ-04-1702) LV305, G305, LV305-matching placebo - Synovial Sarcoma, Cancer | Phase 3 | Terminated | Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 1 | 2018-09-18 | 2020-04-16 |
| Mix Vaccine for Metastatic Sarcoma Patients Mix vaccine - Metastatic Sarcoma, Reaction - Mixed Vaccine | Phase 1 / Phase 2 | Completed | Fuda Cancer Hospital, Guangzhou | 30 | 2017-11-30 | 2019-09-12 |
| Dose-Escalation and Expansion Trial of NC-6300 in Patients With Advanced Solid Tumors or Soft Tissue Sarcoma NC 6300 - Solid Tumor, Soft Tissue Sarcoma | Phase 1 / Phase 2 | Unknown | NanoCarrier Co., Ltd. | 150 | 2017-06-30 | 2020-02-28 |
| A Phase II Multi-Strata Study of PM01183 as a Single Agent or in Combination With Conventional Chemotherapy in Metastatic and/or Unresectable Sarcomas PM01183, Doxorubicin, Gemcitabine - Metastatic Sarcoma | Phase 2 | Completed | Massachusetts General Hospital | 42 | 2015-08-01 | 2021-03-03 |
| Study to Compare the Safety and Efficacy of CMB305 With Atezolizumab to Atezolizumab Alone in Participants With Sarcoma (IMDZ-C232/V943A-002) CMB305, atezolizumab - Sarcoma, Myxoid/Round Cell Liposarcoma | Phase 2 | Terminated | Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 89 | 2015-04-29 | 2020-07-07 |
Showing 20 of 23. Sign in to see all of them.
Sarcoma (23) · Colorectal Neoplasms (5) · Sarcoma, Synovial (4) · Liposarcoma (3) · Neoplasm Metastasis (3) · Brain Neoplasms (2) · Dermatofibrosarcoma (2) · Histiocytoma, Malignant Fibrous (2) · Leiomyosarcoma (2) · Lung Neoplasms (2) · Melanoma (2) · Pancreatic Neoplasms (2) · Rhabdomyosarcoma (2) · Stomach Neoplasms (2) · Bone Neoplasms (1)
Neoplasms by Histologic Type (23) · Neoplasms, Connective and Soft Tissue (23) · Neoplasms (22) · Neoplasms, Connective Tissue (8) · Neoplasms by Site (7) · Digestive System Diseases (6) · Digestive System Neoplasms (6) · Gastrointestinal Diseases (6) · Gastrointestinal Neoplasms (6) · Colonic Diseases (5) · Intestinal Diseases (5) · Intestinal Neoplasms (5) · Rectal Diseases (5) · Endocrine Gland Neoplasms (3) · Endocrine System Diseases (3)
Doxorubicin (4) · Gemcitabine (3) · Magnetic Resonance Spectroscopy (3) · Biopsy (2) · Docetaxel (2) · Specimen Handling (2) · 2,5,7,8-tetramethyl-2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy acetic acid (1) · 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione (1) · Bevacizumab (1) · Contrast Media (1) · Cryosurgery (1) · Everolimus (1) · FAPI-46 (1) · Fluorescein (1) · Fluoresceins (1)
M.D. Anderson Cancer Center (4) · Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (2) · National Cancer Institute (NCI) (2) · Ann & Robert H Lurie Children's Hospital of Chicago (1) · Brown University (1) · CareAcross (1) · Fred Hutchinson Cancer Center (1) · Fuda Cancer Hospital, Guangzhou (1) · Jonsson Comprehensive Cancer Center (1) · Lantheus Medical Imaging (1) · Massachusetts General Hospital (1) · Mayo Clinic (1) · Mohammed M Milhem (1) · NCIC Clinical Trials Group (1) · NanoCarrier Co., Ltd. (1)
United States (20) · Canada (2) · China (1) · Greece (1)
Atsushi Osada (1) · Bradley DeNardo, MD (1) · Brendan Curti, MD (1) · Candace L Haddox (1) · Don S Dizon, MD (1) · Emmanuel M Gabriel, M.D., Ph.D. (1) · Gregory Cote, MD PhD (1) · James Freddo, MD (1) · Jeremie Calais, MD (1) · Jordi Rodon Ahnert (1) · Joseph Ludwig, MD (1) · Megan Shen (1) · Mohammed Milhem, MD (1) · Quincy Chu (1) · Rahul A Sheth, MD (1)
PMID 12001988, PMID 17704903, PMID 19906081, PMID 19917863, PMID 20061178, PMID 20233873, PMID 20336386, PMID 20374484, PMID 20490982, PMID 20737573, PMID 21153378, PMID 21909917, PMID 21926464, PMID 22162570, PMID 23456602, PMID 24956510, PMID 25013744, PMID 25632070, PMID 26883450, PMID 2801858, PMID 31896519, PMID 33654117, PMID 34260265, PMID 35920783, PMID 37124504, PMID 3808620, PMID 38573872, PMID 40377420, PMID 42191879
UM1CA186709 (2), R01CA180279 (1)